Description: <p><b>Cynanbungeigenin C and D</b> — Cynanbungeigenin C (CBC) and Cynanbungeigenin D (CBD) are a pair of epimeric C21 steroidal natural products isolated from <i>Cynanchum bungei</i> Decne. They are best classified as plant-derived small-molecule Hedgehog pathway inhibitors, with reported activity at or near the GLI transcriptional effector level rather than as canonical Smoothened-only inhibitors. The abbreviation CBC/D is preferable in this database entry because CBC and CBD also commonly refer to cannabinoids.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Hedgehog pathway suppression through GLI-level blockade, reducing downstream GLI1-dependent transcriptional output.</li>
<li>Suppression of Hedgehog-dependent medulloblastoma growth and tumor-propagating signaling.</li>
<li>Anti-proliferative and pro-apoptotic tumor effects, strongest evidence currently from medulloblastoma models for CBC/D and colorectal cancer models for the CBC derivative CBC-1.</li>
<li>Drug-development constraint: poor aqueous solubility of parent CBC, motivating CBC-1 derivative synthesis with improved solubility and stronger colorectal cancer activity.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Human pharmacokinetics, oral bioavailability, metabolism, and clinically achievable exposure are not established. Parent CBC has reported poor water solubility; CBC-1 was developed partly to improve this limitation. Mouse in-vivo activity is preclinical and should not be treated as evidence of human exposure feasibility.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> The mechanistic evidence is concentration-driven and mostly preclinical. Because human PK data are absent, common in-vitro concentrations cannot yet be judged against achievable systemic exposure. Solubility and formulation are central translation constraints.</p>
<p><b>Clinical evidence status:</b> Preclinical only. Evidence consists mainly of natural-product isolation, cell-based Hedgehog/GLI assays, medulloblastoma tumor models, and a newer CBC-derived GLI1 inhibitor study in colorectal cancer. No human oncology trials or regulatory approval were identified for CBC/D or CBC-1.</p>
<h3>CBC/D Cancer Mechanism Matrix</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>GLI transcriptional output</td>
<td>↓ GLI signaling</td>
<td>Not established</td>
<td>G</td>
<td>Blocks Hedgehog signaling at the GLI level</td>
<td>Core mechanism for CBC/D in Hedgehog-dependent medulloblastoma; CBC-1 derivative evidence supports direct GLI1 targeting in CRC models.</td>
</tr>
<tr>
<td>2</td>
<td>Hedgehog pathway</td>
<td>↓ HH pathway activity</td>
<td>Not established</td>
<td>G</td>
<td>Suppresses oncogenic HH pathway dependence</td>
<td>Most relevant where tumors depend on SHH/HH-GLI signaling; likely context-dependent across cancers.</td>
</tr>
<tr>
<td>3</td>
<td>Medulloblastoma growth</td>
<td>↓ proliferation and tumor growth</td>
<td>Not established</td>
<td>G</td>
<td>Antitumor activity in HH-dependent medulloblastoma models</td>
<td>Parent CBC/D evidence is strongest in this disease model rather than broad pan-cancer evidence.</td>
</tr>
<tr>
<td>4</td>
<td>Apoptosis</td>
<td>↑ apoptosis</td>
<td>Not established</td>
<td>G</td>
<td>Cell death secondary to GLI1 suppression</td>
<td>Best documented for CBC-1 derivative in colorectal cancer; parent CBC/D apoptosis evidence should be marked derivative-supported unless confirmed in the original paper.</td>
</tr>
<tr>
<td>5</td>
<td>Tumor progression</td>
<td>↓ tumor-propagating capacity</td>
<td>Not established</td>
<td>G</td>
<td>Reduced malignant growth phenotype</td>
<td>tumor cell proliferation or tumor progression suppression; external evidence supports growth suppression more clearly than migration-specific effects.</td>
</tr>
<tr>
<td>6</td>
<td>ROS NRF2 Ca²⁺ Glycolysis HIF-1α</td>
<td>Not established</td>
<td>Not established</td>
<td>G</td>
<td>No primary evidence found</td>
<td>Do not force redox, NRF2, calcium, glycolysis, or hypoxia axes unless a direct CBC/D paper supports them.</td>
</tr>
<tr>
<td>7</td>
<td>Clinical Translation Constraint</td>
<td>Solubility-limited parent compound</td>
<td>Safety window not established</td>
<td>G</td>
<td>PK and formulation uncertainty</td>
<td>Parent CBC poor water solubility and absent human PK are the main database constraints; CBC-1 derivative improves solubility but remains preclinical.</td>
</tr>
</tbody>
</table>
<p><b>TSF legend:</b></p>
<p>P: 0–30 min</p>
<p>R: 30 min–3 hr</p>
<p>G: >3 hr</p>